AVTX
Avalo Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.59 EPS
Last earnings -0.5% on 2026-05-13
$17.83
▲ +4.39%$17.83▲ +298.88%
over 1Y
L $4.47EODHDH $22.87
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+4.4%
1W+24.4%
1M+11.3%
3M+32.6%
YTD+4.8%
1Y+298.9%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.40x); but revenue fell -86.6% YoY.
Avalo Therapeutics, Inc. shows $59.0K in FY2025 revenue (-86.6% YoY), a -132642.4% net margin, and -94.2% ROE.
Sources: SEC EDGAR (CIK 0001534120, latest 10-Q filed 2026-05-13) · EODHD · as of 6/24/2026, 9:46:07 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.